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Myocardial stunningCoronary artery disease (CAD) is themost prevalent and singlemost common cause ofmorbidity andmortality [1]
with the resulting left ventricular (LV) dysfunction an important complication. The distinction between viable and
non-viablemyocardium in patients with LV dysfunction is a clinically important issue among possible candidates
formyocardial revascularization. Several available non-invasive techniques are used to detect and assess ischemia
and myocardial viability. These techniques include echocardiography, radionuclide images, cardiac magnetic
resonance imaging and recentlymyocardial computed tomography perfusion imaging. This review aims to distin-
guish between the available non-invasive imaging techniques in detecting signs of functional and perfusion via-
bility and identify those which have the most clinical relevance in detecting myocardial viability in patients
with CAD and chronic ischemic LV dysfunction. The most current available studies showed that both myocardial
perfusion and function based on non-invasive imaging have high sensitivity with howeverwide range of speciﬁc-
ity for detecting myocardial viability. Both perfusion and function imaging modalities provide complementary
information about myocardial viability and no optimum single imaging technique exists that can provide very
accurate diagnostic and prognostic viability assessment. The weight of the body of evidence suggested that
non-invasive imaging can help in guiding therapeutic decision making in patients with LV dysfunction.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Because of high mortality rate and increasing prevalence of heart
failure and the need to tailor therapy to the etiology and stage of the
condition, testing of patients with heart failurewill become increasingly
common [2]. Non-invasive imaging can help identify viable segments of
myocardium that have greater likelihood of improving functionally
when an adequate blood supply is restored. Echocardiography, radionu-
clide images, cardiacmagnetic resonance imaging and recentlymyocar-
dial computerized tomography perfusion imaging are used to detect
and assess ischemia and myocardial viability. These imaging modalities
detect signs of myocardial viability through contractile reserve in
response to low dose dobutamine, intact cell membrane or residual
glucose utilization.
2. Deﬁnition and historical perspective of myocardial viability
Myocardial viability is the myocardiumwith a potentially reversible
contractile dysfunction in patients with chronic CAD. MyocardialUniversity, Medway Campus,
itime, Kent ME4 4UF, UK.
lmo@yahoo.com (I.A. Elﬁgih).
land Ltd. This is an open access articlstunning is deﬁned as a prolonged contractile myocardial dysfunction
after a transient acute ischemia, whereas dysfunctional myocardium
which improves after coronary revascularization is deﬁned as myocar-
dial hibernation [3,4]. Myocardial viability has been clinically recog-
nized for more than 40 years ago. The term ‘myocardial viability’
adopted by clinicians relies on a clinical phenomenon that is potentially
salvageable with treatment using revascularization, drugs or devices.
The prognostic beneﬁt is measured by patient's survival and symptom-
atic improvement or with cardiac function measurements.
For more than four decades, several observational trials have identi-
ﬁed the reversible myocardial dysfunction post revascularization in
patients with CAD and showed that ischemic LV dysfunction is not
always irreversible. In 1973, Chatterjee et al. reported improved myo-
cardial wall motion abnormalities following revascularization in the
CAD patients in the absence of myocardial scar [5]. A year later, Horn
et al. (1974) concluded that myocardial wall motion abnormalities im-
proved by inotropic stimulation with epinephrine infusion in patients
with CAD and LV asynergy [6]. Rahimtoola and Braunwald in the mid
eighties used the term myocardial hibernation to describe a condition
of abnormal resting ventricular function because of chronic hypo-
perfusion in CAD patients [3,4,7,8]. As a result of coronary blood ﬂow
reduction, acute and chronic adaptations of the myocardium prevent
irreversible myocardial damage.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
52 I.A. Elﬁgih, M.Y. Henein / IJC Heart & Vasculature 5 (2014) 51–563. Imaging techniques employed for viability assessment
Several non-invasive imaging modalities are used to assess myocar-
dial viability and to identifymarkers of functional recovery. These imag-
ing modalities have different diagnostic accuracy and limitations [9].
Assessment of systolic function and contractile reserve within areas of
dysfunction are based on the imaging of dysfunctional myocardium
using dobutamine stress echocardiography, Doppler tissue imaging
and dobutamine stress cardiac magnetic resonance (CMR). Assessment
of perfusion is based on the documentation of cell integrity using
contrast echocardiography and nuclear techniques (SPECT and PET) by
perfusion tracers or a combination ofmetabolic andperfusion tracers, re-
spectively. Moreover, delayed enhancement CMR imaging and more re-
cently multi slice computer tomography (MSCT) delayed enhancement
imaging can deﬁne necrotic myocardium. For diagnostic and prognostic
viability assessment, the relative merits of non-invasive myocardial
function imaging as compared to myocardial perfusion imaging are
discussed.
3.1. Non-invasive myocardial function imaging
3.1.1. Dobutamine stress echocardiography
Dobutamine stress echocardiography (DSE) is themostwidely used
modality and most extensively studied test for the assessment of myo-
cardial viability. Contractile reserve is the most common criterion used
to detect viable myocardium. Usually low dose Dobutamine is used by
infusion of 5–10 mcg/kg/min Dobutamine which increases contractili-
ty in dysfunctional but viable myocardium while nonviable myocardi-
um does not show this contractile reserve. In 1997 a meta-analysis by
Bax et al. pooled 37 studies showed an overall sensitivity of 84% and
speciﬁcity of 81% as compared with other imaging techniques, DSE
has an overall similar sensitivity and the highest speciﬁcity [10]. In ad-
dition, pooled data by Bax et al. (2001) evaluated the detection of hi-
bernating myocardium and utilized myocardial perfusion images and
DSE [11]. However, most of these studies did not compare imaging
techniques in the same patients [12]. FDG-PET, reinjection thallium
SPECT, and DSE had the highest negative predictive values while
rest–redistribution thallium SPECT and technetium sestamibi SPECT
had lower values. The highest positive predictive value was seen with
DSEwith intermediate values for other forms of radionuclidemyocardi-
al perfusion imaging of 84% versus 75% except reinjection thallium
SPECT which had the lowest value. However, DSE had the lowest
negative predictive values in comparison with FDG-PET and reinjection
thallium SPECT of 69% versus 80%. Furthermore, for the prediction of an
improvement in LV ejection fraction (EF) after revascularization, DSE
had the highest positive and negative predictive values compared
with nuclear imaging (77% versus 70% and 85% versus 78%, respective-
ly) [11]. Similar results have recently been conﬁrmed by Schinkel et al.
(2007) [13].
3.1.2. End diastolic wall thickness
End diastolic wall thickness (EDWT) may provide the simplest
method to identify myocardial viability. This approach uses a cut-off
value of ≥5.5–6 mm in most studies to determine whether a segment
is viable [14]. Echocardiography and CMR can be used to measure the
EDWTwith the advantage of CMR that provides accuratemeasurements
of the entire LV wall. In a meta-analysis study that used echocardiogra-
phy and nuclear imaging [15], EDWTpredicted functional recoverywith
a sensitivity of 94% but low speciﬁcity of 48%whichwere comparable to
CMR-based wall thickness measurements results reported in a recent
meta-analysis [16].
3.1.3. Myocardial strain imaging
More information on myocardial viability can be obtained by strain
and strain rate. Strain is the deformation of an object relative to its
original length and strain rate is the gradient of velocities betweentwo points in space. Strain and strain rate imaging can be obtained
either from color tissue Doppler imaging or 2D speckle tracking [17].
Echocardiography and CMR can be used to quantify myocardial strain
and strain rate. Strain rate imaging, 2D speckle tracking and myocardial
tagging may improve accuracy in detecting myocardial viability. In a
study by Hoffmann R et al. (2002), strain rate imaging in combination
with low dose dobutamine was used to improve assessment of viable
myocardium in 37 patients with ischemic cardiomyopathy. An increase
of peak systolic strain rate of ≥0.23/s had a sensitivity of 83% and
speciﬁcity of 84% [18]. In addition, adenosine speckle tracking could
be used to discriminate viable fromnon-viablemyocardiumwith stress.
In a recent small trial by Ran et al. (2012), 36 patients who had
sustained previous MI and EF of 40% (±6%) were assessed and showed
that using adenosine stress, radialmyocardial strainmore than 9.5% had
a sensitivity of 83.9% and a speciﬁcity of 81.4% for detecting viable myo-
cardium, whereas a change of longitudinal strain more than 14.6%
displayed a sensitivity of 86.7% and a speciﬁcity of 90.2%. Peak-systolic
circumferential strain however, had little effect on viability assessment.
The study concluded that 2D speckle tracking imaging combined with
adenosine stress echocardiography could be reliable method to detect
viable myocardium [19].
3.1.4. Dobutamine stress CMR
Dobutamine stress CMR is based on the same principle as in the DSE
that determines the contractile reserve of dysfunctionalmyocardium by
administrating low dose dobutamine of 5–10 mcg/kg/min, viable myo-
cardium will show an increased contractile function and non-viable
myocardium will remain unchanged [20]. A recent meta-analysis by
Romero et al. (2012) pooled nine studies assessing low dose dobuta-
mine stress CMR showed that meanweighted sensitivity and speciﬁcity
for low dose dobutamine stress CMR were 81% and 91%, whereas the
PPV and NPV were 93% and 75%, respectively. Low dose dobutamine
stress CMR showed the highest speciﬁcity in comparison with LGE
and end-diastolic wall thickness [16].
Low dose dobutamine stress CMR and DSE are comparable as shown
by Baer et al. (2000) in head to head study comparing dobutamine
stress CMR and dobutamine stress transoesophageal echocardiography
for predicting recovery of ventricular function post revascularization in
patients with chronic CAD [21]. Both tests were highly accurate where
the respective values of sensitivity and speciﬁcity for echocardiography
were 82% and 83%, whereas for the CMR were 86% and 92%, respective-
ly. A small study by Wellnhoffer et al. enrolled 29 patients suggested
that low dose dobutamine stress CMRwas superior to LGE in predicting
improvement in wall motion of dysfunctional segments with 1–74%
transmural extent of myocardial infarction after revascularization [22].
In addition, a study by Bove et al. demonstrated a similar improvement
in percentage of wall thickness and LV function with low dose dobuta-
mine in segments with 1–50% transmural infarction after revasculariza-
tion [23]. Other studies suggested that the combination of LGE and low
dose dobutamine stress CMR may offer a more reliable method of
assessing myocardial viability [24,25]. A recent study demonstrated
that combination of CMR viability parameters, contractile reserve by
low dose dobutamine, EDWT and scar quantiﬁcation improved the pre-
diction of function recovery [26].
3.2. Non-invasive myocardial perfusion imaging
3.2.1. Myocardial contrast echocardiography
Myocardial contrast echocardiography (MCE) uses intravenous
contrast agents composed of high molecular weight inert gases which
produce microbubbles which behave like red blood cells and stay in
the vascular space thus allow direct visualization of myocardial perfu-
sion. The intensity of myocardial contrast reﬂects the myocardial
blood ﬂow. Therefore, dysfunctional segments are classiﬁed as viable
when segments have normal or patchy perfusion and nonviable when
segments have no perfusion [15].
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ning from necrotic tissues [27]. Microvascular integrity is a prerequisite
of the technique to detect myocardial viability in dysfunctional seg-
ments. It has been shown that after acute myocardial infarction (MI),
MCE has a high sensitivity and NPV of N90% in predicting functional
recovery with low speciﬁcity (65%) but better than with SPECT imaging
[28]. Recently, a review by Hayat et al. (2008) in the setting of ST-
elevation MI showed that MCE had a high sensitivity of 82% for
predicting functional recovery after revascularization but equivalent
speciﬁcity compared with DSE. MCE and cardiac MRI were comparable
in predicting functional recovery [29].
MCE has also been used to assess myocardial viability in patients
with chronic LV dysfunction.MCE using direct intra-coronary injections
of microbubbles has been compared with DSE and thallium-201 rest
redistribution SPECT in 18 patients undergoing revascularization. MCE
and rest SPECT had high sensitivity for detecting a hibernating myocar-
dium ranging from 62% to 92% and a low speciﬁcity from 67% to 87% for
predicting regional functional recovery compared with DSE [30]. A
study by Shimoni et al. using quantitative intravenous MCE showed
that MCE has a high sensitivity of 90% which was similar to Tl-201
SPECT (92%) and superior to DSE (80%); the speciﬁcity was higher for
MCE (63%) than for Tl-201 SPECT and DSE (45% and 54%, respectively)
[31]. Therefore, generally MCE is sensitive but not speciﬁc for the pre-
diction of functional recovery. However, the speciﬁcity can be improved
by integrating MCE and DSE to allow more information on perfusion
and contractile reserve thus high likelihood to improve in function
after revascularization [32,33].
3.2.2. Single-photon emission computed tomography (SPECT)
SPECT is one of the non-invasive nuclear imaging techniques most
frequently performed to detectmyocardial viability. Viablemyocardium
is identiﬁed by demonstrating the myocyte membrane integrity
through the extent of myocardial uptake of the radioactive tracers.
The radioactive tracers used in clinical practice include Thallium-201
or Technetium (Tc)-99 m or Tc-99 m tetrofosmin, with Tc-99 m
sestamibi being the most widely used tracer in clinical practice.
Several comparative studieswith thallium reinjection and PET imag-
ing with FDG demonstrated a correlation between viable segments
deﬁned by thallium reinjection and the metabolic evidence of viable
myocardium deﬁned by PET [34]. It has been shown that Technetium-
99 m sestamibi has lower predictive values compared with thallium-
201 [35] but in other studies Technetium-99 m sestamibi and thallium-
201 were comparable in predicting functional recovery [36]. Recently,
Schinkel AF et al. (2007) analysis of 24 studies using thallium-201
SPECT and technetium-99 m sestamibi SPECT in predicting segmental
functional recovery after revascularization showed a similar high sensi-
tivity of 87% (range 76%–96%) versus 83% (range 72%–96%), respective-
ly whereas technetium-99 m sestamibi SPECT had a better speciﬁcity
than thallium-201 SPECT of 65% (range 53%–88%) versus 54% (range
25%–65%) [13].
3.2.3. Positron Emission Tomography (PET)
Cardiac PET detects myocardial viability by using a combined per-
fusion assessment with Nitrogen-13 labeled ammonia (13NH3) or
Rubidium-82 or Oxygen-15 water that quantify myocardial blood ﬂow
and metabolic assessment with Fluorine-18-deoxyglucose (FDG-18).
The most commonly used technique is by combined perfusion (13NH3)
and metabolic FDG-18 PET “tracer combination technique”. PET is
considered highly accurate in diagnosing myocardial perfusion abnor-
malities [15].
Over the years, many studies employed nuclear imaging comparing
the perfusion SPECT technique with metabolic PET technique; most of
these studies concluded equivalent results. Bonow et al. (1991) report-
ed an 88% concordance between stress, delayed, and reinjection Tl-201
and 18F-FDG-PET imaging. Regions with mild to moderate Tl-201
defects were viable and also had metabolically viable myocardiumwith FDG-18 PET [34]. Siebelink et al. (2001) found no difference in
patient management or cardiac event-free survival when compared
(13N)-ammonia or 18F-FDG PET guided management with stress or
rest Tc-99 m sestamibi SPECT guided management. They suggested
that in management decision both imaging techniques were compara-
ble and may be used for viability detection [37].
In a pooled 19 studies based on six PET and 13 SPECT, thalliumSPECT
compared to PET showed higher sensitivitywith highNPV of 90% versus
83% and lower speciﬁcity with low PPV of 69% versus 82%, respectively
in predicting recovery of ventricular function [38]. A meta-analysis by
Allman et al. (2002) of 24 observational studies involving 3088 patients
showed that both nuclear imaging had a similar ability to predict a
survival beneﬁt after revascularization [39]. However, there were stud-
ies showing that the detection of viability by metabolic PET had higher
sensitivity and speciﬁcity than perfusion SPECT. Rohatgi et al. reported
that PET detect a signiﬁcant amount of viable myocardium in almost
60% of ischemic cardiomyopathy patients which indicated by thallium
SPECT as a scar, in addition to a signiﬁcant improvement in survival
after revascularization in compared to medical treatment alone [40].
In 2004, a meta-analysis by Underwood SR et al. found that both
SPECT and PET demonstrated high sensitivity [12]. The recent analysis
by Schinkel AF et al. (2007) pooled 24 studies (756 patients) noted
that PET had highest sensitivity compared with SPECT with weighted
mean sensitivities and speciﬁcities of 92% and 63%, respectively, and
higher positive and negative predictive values of 74% and 87% respec-
tively for the prediction of regional ventricular function post revascular-
ization [13].
3.2.4. Late-gadolinium enhancement CMR (LGE-CMR)
Contrast enhanced CMRwith gadoliniumwas ﬁrst described in 1984
and has proved useful in detecting infarcted tissue, which appear hyper
enhanced. Kim et al. ﬁrst demonstrated the potential of LGE-CMR in the
assessment of myocardial viability over a decade ago. They demonstrat-
ed hyper enhancement in acute and chronic myocardial infarcted areas
while no hyper enhancement in the reversible damaged myocardial
areaswas seen [41]. In 2000, they found that the likelihood of functional
recovery of the myocardium after revascularization decreased progres-
sively as the transmural extent of LGE before revascularization
increased [42]. In a meta-analysis by Romero et al. (2012), LGE CMR
demonstrated the highest sensitivity of 95% with speciﬁcity of 51%,
PPV of 69% andNPP of 90% for predicting regional wallmotion improve-
ment after revascularization [16]. In 2007 a prospective cohort trial (29
patients) demonstrated that LGE-CMR and PET/SPECT were equally
effective in determining myocardial viability [43]. Furthermore, several
studies have supported the latter ﬁnding and have additionally demon-
strated that LGE-CMR is superior to DSE in certain patients, including
those with poor images or arrhythmias for the detection of viability
[25,44].
3.2.5. Multi slice computerized tomography
Multi slice CT (MSCT) technology has been introduced to assess
myocardial viability due to recent advances in its temporal and spatial
resolutions. Several studies in patients with MI compared the accuracy
of the late contrast enhanced CT with LGE CMR demonstrated a similar
accuracy in the detection of myocardial viability [45,46], although,
a systematic underestimation of infarct size by MSCT have reported
[47]. In addition, delayed enhancement and early perfusion defects on
MSCT can predict myocardial function recovery three months after
acute MI. Delayed enhancement MSCT had a respective sensitivity and
speciﬁcity of 73% and 85% whereas early perfusion defects had a sensi-
tivity and speciﬁcity of 57% and 90%, respectively [48]. Compared with
SPECT, MSCT has also been shown to accurately detect healed MI [49].
Moreover, when comparedwith DSE and SPECT, LVwith N75% segmen-
tal extent of infarcted myocardium by MSCT were correlated to the
decreased uptake by SPECT and contractile reserve by DSE [50].
Myocardial perfusion images Sensitivity Speciﬁcity PPV NPV
MCE [28] 82% 74% ……. ……..
SPECT thallium-201 imaging [12] 87% 54% 67% 79%
SPECT Tech-99 m Sestamibi [12] 83% 65% 74% 76%
PET [12] 92% 63% 74% 87%
LGE-CMR [15] 95% 51% 69% 90%
MSCT (ED vs LE) [47] 57% vs 73% 90% vs 85% ……. ……..
(continued on next page)
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Observational studies employing non-invasive imaging in patients
with ischemic LV dysfunction have pointed out toward detection of
myocardial viability as a target for prognostic revascularization and
other therapies. Despite that many of these studies were small, from a
single center, predated the advent of current medical and device thera-
pies for heart failure and predated the new modalities such as PET and
CMR but these studies emerge data regarding improvements after
revascularization. Several clinical endpoints tested by non-invasive
imaging modalities improved after revascularization including regional
LV improvement, global LV improvement in the formof LV EF, heart fail-
ure symptoms (NYHA class) and exercise capacity in addition to reverse
LV remodeling as well as survival beneﬁt.
Predicting improvement in LV function was evaluated in a meta-
analysis by Schinkel AF et al. (2007) that analyzed the prediction of
improvement of regional contractile function after revascularization
[13]. Individual technique mean sensitivity and speciﬁcity was: DSE,
74% and 82%; SPECT, 83%–87% and 54%–68%; PET, 92% and 63%; LGE-
CMR, 84% and 63% and dobutamine stress CMR, 88% and 87%. Nuclear
techniques tended to have higher sensitivity and low speciﬁcity as
compared to DSE. However, many studies evaluated regional LV
improvement after revascularization rather than global (LV ejection
fraction) improvement [13]. From a clinical perspective, global LV
improvement and eventually survival improvement are more impor-
tant than regional LV recovery [15]. The meta-analysis published by
Underwood et al. demonstrated an improvement in LV ejection fraction
in patients with viable myocardium whereas no change in those with-
out hibernation [12].
In addition, improvement of symptoms and exercise capacity
correlated with the extent of viable myocardium after revasculariza-
tion [13]. However, Marwick and colleagues (1999) failed to demon-
strate a relation between PET assessed viability and improvement of
exercise capacity after revascularization [51]. Furthermore, improve-
ment of LV geometry of viable myocardium after revascularization
contributes to better LV systolic function, which subsequently im-
proves patient's prognosis [52]. Indeed, patients with evidence for via-
ble myocardium and large LV size demonstrated a high event rate
(67%) as compared to those with viable myocardium and small LV
size (5%) [53].
Survival beneﬁt after revascularization in patients with deﬁned
viability by any imaging modalities was observed in several pooled
analyses [37,54]. A recent meta-analysis pooled 9 studies using PET
showed the highest mortality rate in patients with viable myocardium
who were treated medically compared to those who were revas-
cularized [55]. Similar survival beneﬁt was noted in another review by
Underwood SR et al. (2004) in patients with viable myocardium after
revascularization in which annual mortality rate was reduced by 7%
versus 20% in medically treated patients [12].
The large body of data comes from a meta-analysis by Allman et al.
(2002) of 24 observational studies involving 3088 patients demonstrat-
ed that medically treated patients with deﬁned viability by echocardi-
ography, SPECT and PET compared to non-viable group had an annual
death of 16% versus 6.2%, respectively. Patients with evidence for viable
myocardium on all imaging techniques had a reduced rate of death by
79.6% compared to those without evidence of viable myocardium after
revascularization, with an annual death of only 3.2% in the former
compared with 7.7% in the latter [39]. Similarly, the most recent retro-
spective study using PET imaging demonstrated that a survival beneﬁt
was better with revascularization thanwithmedical therapy in patients
with N10% hibernating myocardium [56].
The viability imaging ﬁndings from previous observational and
retrospective studies have been recently challenged by surprising
contradictory ﬁndings from prospective, randomized trials of a sub-
study of the prospective Surgical Treatment of Ischemic Heart Failure
(STICH) trial and the Canadian PPAR study [57,58]. Both studiesreported a lack of this association between the presence or absence of
residual myocardial viability and patient's mortality outcome when
treatment was allocated to revascularization or medical therapy. How-
ever, several study limitations with potentially confounding effects
may explain the seemingly contrary results, and further trials are need-
ed to explore this outcome.5. Clinical implications
It has been shown that patients with chronic ventricular dysfunction
and CAD have poor long term survival. Identiﬁcation of such patients
who may beneﬁt from revascularization procedures is the major goal
to improve outcomes. Several viability studies have estimated the long
term prognosis as a ﬁnal endpoint and concluded that viable myocardi-
um was related to the improvement in myocardium function.
In addition, selection of patients for the best therapy should not rely
on viability assessment alone. When deciding for revascularization,
other multifactor determinants include; clinical situation, symptoms
and co-morbidities such as diabetes mellitus and renal failure that
may substantially contribute to mortality in the follow-up period,
should be considered. Lack of functional recovery after revascularization
is not always associated with poor patient's outcomes. Survival beneﬁt
of such patients may possibly result from the impact of revasculariza-
tion in other factors that prevent further infarction and death [59].
Thus, despite the increased risk of revascularization, preserved viability
may suggest a net clinical beneﬁt.
The recent ESC and the European Association for Cardio-Thoracic
Surgery (EACTS) guidelines on myocardial revascularization, and the
current ACC/AHA guidelines on heart failure advice that the detection
of viability should be included in the diagnostic work up of patients
with CAD and severe ventricular dysfunction [60–62].6. Conclusion
Non-invasive myocardial imaging plays a pivotal role in the evalua-
tion of viable myocardium in patients with CAD and LV dysfunction
since the presence and extent of viable myocardium have become a
valuable clinical strategy for determining the need for revascularization
and predict the improvement in patient's clinical outcome regarding LV
function recovery, symptoms and survival.
The tables below summarize the most recent available data that
shows high sensitivity for the assessment of myocardial viability for
both non-invasive myocardial perfusion and function modalities.
However, there is a wide range of speciﬁcity varying from 38% up to
91%. Direct comparisons between radionuclide imaging and CMR imag-
ing techniques and dobutamine stress echocardiography in the same
patients are limited. The recommended approach to assess myocardial
viability begins with either functional images in the form of DSE and
Dobutamine stress CMR imaging or perfusion images in the form of
radionuclide myocardial perfusion imaging (SPECT) and LEG-CMR,
depending on availability and local expertise. Furthermore, PET scan-
ning has a greater sensitivity and is a good alternative, however PET,
CMR and MDCT may bemore challenging to perform and not as widely
available. Further studies are needed to determine the incremental
values of MDCT perfusion images.
Myocardial function images Sensitivity Speciﬁcity PPV NPV
EDWT-ECHO [13] 94% 48% 53% 93%
EDWT-CMR [15] 96% 38% 71% 85%
DSE [12] 81% 78% 75% 83%
DSE-SRI [17] 83% 84% ……. …….
Adenosin-SRI [18] 83.9% 81.4% ……. …….
Dobutamine stress CMR [15] 81% 91% 93% 75%
NPV = negative predictive value; PPV = positive predictive value; MCE = Myocardial
contrast echocardiography; SPECT = Single-photon emission computed tomography;
PET = Positron Emission Tomography; LGE-CMR = Late-gadolinium enhancement
CMR; MSCT = Multi slice CT; ED = Early perfusion defects; LE = Late enhancement;
EDWT = End diastolic wall thickness; DSE-SRI = Dobutamine stress echocardiography-
Strain rate images.
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dalities provide complementary information about myocardial viability
in CADpatients and at present, no sole test has evolved to provide all the
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